Talk gets fevered over whether Pfizer, J&J or Lilly might make a run at Cubist

The announcement that the FDA will review a second drug candidate from antibiotic specialist Cubist Pharmaceuticals ($CBST), speculation is ramping up that it is ripe for a takeover. Pfizer ($PFE), which has a competing drug for which Cubist hopes to get FDA approval, is one possible suitor being mentioned. Johnson & Johnson ($JNJ) and Eli Lilly ($LLY) are also mentioned as having the cash and competency to make a run at Cubist. Report | More

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.